Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $75.00

Definium Therapeutics (NASDAQ:DFTX) had its price target hoisted by Robert W. Baird from $57.00 to $75.00 in a research note published on Thursday, MarketBeat Ratings reports. They currently have an outperform rating on the stock.

A number of other equities analysts have also recently issued reports on the company. JonesTrading upped their price objective on Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a report on Wednesday, June 24th. Leerink Partners set a $52.00 price objective on Definium Therapeutics and gave the company an “outperform” rating in a report on Monday, June 22nd. Needham & Company LLC boosted their target price on Definium Therapeutics from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Wednesday. Canaccord Genuity Group set a $58.00 target price on Definium Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Wall Street Zen lowered Definium Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $62.14.

Definium Therapeutics Stock Down 2.9%

Shares of NASDAQ:DFTX opened at $42.63 on Thursday. The firm has a market capitalization of $5.73 billion, a PE ratio of -12.43 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. Definium Therapeutics has a 52-week low of $8.70 and a 52-week high of $49.70. The firm has a fifty day moving average of $39.83 and a 200 day moving average of $26.82.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, research analysts anticipate that Definium Therapeutics will post -2.81 EPS for the current fiscal year.

Insider Buying and Selling at Definium Therapeutics

In other news, CEO Robert Barrow sold 29,208 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer owned 1,098,246 shares in the company, valued at approximately $49,454,017.38. The trade was a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the transaction, the chief financial officer owned 209,487 shares in the company, valued at approximately $9,433,199.61. This represents a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 48,096 shares of company stock valued at $2,165,763. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cerity Partners LLC increased its stake in Definium Therapeutics by 2.4% in the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after purchasing an additional 1,165 shares during the period. Creative Planning lifted its position in Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares during the period. Mercer Global Advisors Inc. ADV boosted its stake in shares of Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after purchasing an additional 2,079 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after purchasing an additional 2,342 shares during the period. 27.91% of the stock is currently owned by institutional investors.

Key Stories Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its Phase 3 VOYAGE study of DT120 ODT in generalized anxiety disorder achieved its primary goals. The treatment produced a 5.4-point improvement on the HAM-A anxiety scale versus placebo, strengthening the case for DT120’s potential efficacy and supporting future regulatory and commercial plans. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: The positive clinical readout has increased confidence in additional DT120 trials and potentially supports the drug’s use across more than one indication. Investors are also watching for a further catalyst expected in September 2026. Definium Therapeutics Hits Phase 3 GAD Goals For DT120 ODT
• Positive Sentiment: Analysts raised their targets following the data: JonesTrading increased its target to $90 from $74 and maintained a Buy rating; Robert W. Baird raised its target to $75 from $57; Wells Fargo lifted its target to $72 from $68; and RBC raised its target to $66 from $57 while assigning an Outperform rating. These revisions indicate substantial perceived upside, although targets are not guarantees. Analyst price-target updates
• Positive Sentiment: Needham reportedly expects DFTX shares to rise, while recent analyst commentary broadly reflects optimism about DT120’s development prospects. Needham analyst outlook
• Neutral Sentiment: Near-term trading may remain volatile as investors assess the Phase 3 results, upcoming milestones, and expectations for third-quarter earnings. HC Wainwright Q3 earnings estimate
• Negative Sentiment: DFTX remains an unprofitable biotechnology company, and its latest reported quarter missed consensus EPS estimates. The stock’s large recent rally and elevated volatility could also encourage profit-taking despite the favorable trial news.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.